'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
CORONA Remedies Limited
CORONA (NSE) · CORONA (BSE 544644) · ISIN INE02ZQ01018 · Pharmaceuticals · listed 2025 · website
Not on any surveillance list
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹422.43 cr and profit after tax ₹60.1 cr.
Next: Board meeting: financial results on 30 October 2026.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹422.43 cr | ₹60.1 cr | 9.83 | 31 Jul 2026 |
| Q4 FY26 standalone | ₹353.09 cr | ₹45.05 cr | 7.37 | 11 May 2026 |
| Q3 FY26 standalone | ₹342.42 cr | ₹41.25 cr | 6.74 | 2 Feb 2026 |
| Q2 FY26 standalone | ₹361.13 cr | ₹52.15 cr | 8.53 | 5 Jan 2026 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹745.97 cr | ₹142.86 cr | ₹1,204.25 cr |
| 30 Sep 2025 standalone | ₹659.06 cr | ₹39.58 cr | ₹976.01 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 69.00% | 4.21% | 16.45% | 31.00% |
Latest filings
- CORONA Remedies Limited has informed the Exchange about Transcript 10 August 2026 · NSE
- CORONA Remedies Limited has informed the Exchange about Link of Recording 3 August 2026 · NSE
- CORONA Remedies Limited has informed the Exchange about Investor Presentation 31 July 2026 · NSE
- CORONA Remedies Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Press Release on Unaudited financial results for Q1FY27". 31 July 2026 · NSE
- CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 31 July 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.